1. Market Research
  2. > Biotechnology
  3. > Biopharmaceutical Market Trends
  4. > Competitor Analysis: VEGF Antibodies – Bevacizumab and Ranibizumab Biosimilars and Biosuperiors

VEGF Antibodies – Bevacizumab and Ranibizumab Biosimilars and Biosuperiors

The present Competitive Intelligence Report about VEGF Antibodies – Bevacizumab and Ranibizumab Biosimilars and Biosuperiors provides a competitor evaluation in the field of recombinant antibodies targeting vascular endothelial growth factor (VEGF) used to treat various cancers and ophthalmic diseases as of February 2014. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.


The first generation of recombinant antibodies targeting VEGF consists of bevacizumab (Avastin) from Roche (Genentech) and ranibizumab (Lucentis) from Roche (Genentech) and Recently, VEGF-Trap Eye originating from Regeneron Pharmaceuticals has been approved for cancer and ophthalmic indications. Combined sales of all four VEGF targeting products were US$ 13,192 mln in 2013, of which 53.4% were from oncology sales.


The commercial success of the VEGF antibodies and the expiry of patent protection has laid the ground for development of second generation 'biobetter or biosuperior ' molecules as well as of biosimilar copies of the originator products.


The report includes a compilation of currently active projects in development of VEGF and VEGF-R targeting antibodies for treatment of cancer and neo-angiogenic eye diseases. In addition, the report lists company-specific R&D pipelines of VEGF antibodies. Competitor projects are listed in a tabular format providing information on:


- Drug Codes,
- Target / Mechanism of Action,
- Class of Compound,
- Company,
- Product Category,
- Indication,
- R&D Stage and
- additional comments with a hyperlink leading to the source of information.


About Competitor Analysis Series:

The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.



Table Of Contents

Competitor Analysis: VEGF Antibodies - Bevacizumab and Ranibizumab Biosimilars and Biosuperiors
Competitor Analysis: VEGF Antibodies - Bevacizumab and Ranibizumab Biosimilars and Biosuperiors

Table of Contents


1. Bevacizumab Biosimilars and Biosuperiors

Marketed VEGF Antibodies

-           Avastin Sales and Pipeline

-           Zaltrap Sales and Pipeline

'Next Generation Avastinandrdquo; Pipeline

-           Anti-VEGF Antibody Pipeline

-           Anti-VEGF-Receptor Antibody Pipeline

-           Bispecific Anti-VEGF Antibody Pipeline

Avastin Biosimilar Pipeline


2. Ranibizumab Biosimilars and Biosuperiors

Marketed VEGF Antibody

-           Lucentis Sales and Pipeline

-           Eylea Sales and Pipeline

'Next Generation Lucentisandrdquo; Pipeline

Lucentis Biosimilar Pipeline


3.  Corporate VEGF Antibody Biosimilar and Biobetter Pipelines



View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Biosimilars Market by Product, Manufacturing, Application - Global Forecast to 2021

Biosimilars Market by Product, Manufacturing, Application - Global Forecast to 2021

  • $ 5650
  • Industry report
  • January 2017
  • by MarketsandMarkets

Biosimilars Market by Product (Recombinant Non-glycosylated Proteins (Insulin, rHGH, Interferon), glycosylated (mAb, EPO), Peptides (Glucagon, Calcitonin)), Manufacturing (In-House, CM0) & Application ...

Insulin Biosimilars - Global Market Outlook (2016-2022)

Insulin Biosimilars - Global Market Outlook (2016-2022)

  • $ 4157
  • Industry report
  • October 2016
  • by Stratistics MRC

According to Stratistics MRC, the Global Insulin Biosimilars market is accounted for $xx million in 2015 and is expected to reach $xx million by 2022 growing at a CAGR of xx% from 2015 to 2022. Growing ...

Global Biosimilar Drug Market Research Report 2016

Global Biosimilar Drug Market Research Report 2016

  • $ 2850
  • Industry report
  • November 2016
  • by 9Dimen Research

2016 Global Biosimilar Drug Industry Report is a professional and in-depth research report on the world's major regional market conditions of the Biosimilar Drug industry, focusing on the main regions ...


ref:plp2014

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.